4992 | Candidate COVID-19 Vaccine (COV001), 2020 | 2 | 1 | 0 | excluded | | risk of bias not avaialble |
5682 | AstraZeneca Oxford COV003 phase 3, 0 | 1 | 1 | 0 | | | risk of bias not avaialble |
5810 | AstraZeneca phase 3 US (D8110C00001), 2021 | 1 | 1 | 0 | | | risk of bias not avaialble |
6103 | Folegatti, 2020 | 0 | 1 | 0 | selection pending |
6444 | Barrett, 2020 | 2 | 0 | 0 | excluded | | risk of bias not avaialble |
6664 | Scotland cohort, 0 | 1 | 10 | 0 | | not a RCT | risk of bias not avaialble |
6965 | Bernal (PHE, 19th February 2021), 2021 | 1 | 13 | 0 | | not a RCT | risk of bias not avaialble |
6975 | Corchado-Garcia, 2021 | 0 | 13 | 0 | selection pending |
7012 | Pottegard, 2021 | 1 | 15 | 4 | | not a RCT | high risk of bias |
7017 | John, 2021 | 0 | 0 | 0 | selection pending |
7022 | Bernal, 0 | 1 | 13 | 0 | | not a RCT | risk of bias not avaialble |
7939 | Com-COV, 2021 | 1 | 1 | 0 | | | risk of bias not avaialble |
8252 | Edward (Vaxzevria), 2021 | 1 | 13 | 4 | | not a RCT | high risk of bias |
8267 | Burn (Vaxzevria), 2021 | 1 | 13 | 4 | | not a RCT | high risk of bias |
9070 | Tobaiqy M, 2021 | 2 | 32 | 0 | excluded | not a RCT | risk of bias not avaialble |
9216 | Sultan, 2022 | 0 | 12 | 0 | selection pending |
9221 | Bonelli, 2022 | 0 | 0 | 0 | selection pending |
9232 | Com-COV2, 2022 | 1 | 1 | 0 | | | risk of bias not avaialble |
9234 | Asano, 2022 | 1 | 1 | 0 | | | risk of bias not avaialble |
9244 | Richardson, 2022 | 0 | 0 | 0 | selection pending |
9268 | Nguyen, 2021 | 0 | 11 | 0 | selection pending |
9296 | Hippisley-Cox, 2021 | 1 | 12 | 0 | | not a RCT | risk of bias not avaialble |
9297 | Simpson (ChAdOx1), 2021 | 1 | 12 | 0 | | not a RCT | risk of bias not avaialble |
9313 | EPIPHARE (Vaxzevria), 2022 | 1 | 12 | 0 | | not a RCT | risk of bias not avaialble |
9356 | AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 | 1 | 1 | 0 | | | risk of bias not avaialble |
9360 | Husby (Astra), 2021 | 1 | 12 | 0 | | not a RCT | risk of bias not avaialble |
9370 | Kanokudom, 2022 | 0 | 0 | 0 | selection pending |
9376 | Nanthapisal, 2022 | 2 | 1 | 0 | excluded | | risk of bias not avaialble |
9467 | Clemens, 2021 | 0 | 10 | 0 | selection pending |
9492 | Patone, 2021 | 1 | 12 | 0 | | not a RCT | risk of bias not avaialble |
9614 | Rearte, 2022 | 0 | 12 | 0 | selection pending |
10189 | AstraZeneca phase 3 US (D8110C00001) 6 month follow up, 2021 | 1 | 1 | 0 | | | risk of bias not avaialble |
10190 | Valim, 2022 | 0 | 0 | 0 | selection pending |